Fosun-BioNTech COVID-19 vaccine completes China regulator re

[yash]

Thu, July 15, 2021, 11:16 AM
Fosun-BioNTech COVID-19 vaccine completes China regulator review - media
us.yahoo.com/news/fosun-biontech-covid-19-vaccine-031627609.html


News & Events
February 25, 2021
Small molecule enzyme inhibitor
(sold to Fosun Pharma in 2017, MNKD eligible for royalty payments)

mannkindcorp.com/pipeline-item/small-molecule-enzyme-inhibitor-sold-to-fosun-pharma-mnkd-eligible-for-royalty-payments/

** Not sure if it is related good news for MNKD?

[goyocafe]

Jul 15, 2021 1:29:09 GMT -5 yash said:

Thu, July 15, 2021, 11:16 AM
Fosun-BioNTech COVID-19 vaccine completes China regulator review - media
us.yahoo.com/news/fosun-biontech-covid-19-vaccine-031627609.html


News & Events
February 25, 2021
Small molecule enzyme inhibitor
(sold to Fosun Pharma in 2017, MNKD eligible for royalty payments)

mannkindcorp.com/pipeline-item/small-molecule-enzyme-inhibitor-sold-to-fosun-pharma-mnkd-eligible-for-royalty-payments/

** Not sure if it is related good news for MNKD?

Low single digits? It’s anyone’s guess, but history suggests this won’t amount to much.

[peppy]

Jul 15, 2021 6:34:45 GMT -5 goyocafe said:

Jul 15, 2021 1:29:09 GMT -5 yash said:

Thu, July 15, 2021, 11:16 AM
Fosun-BioNTech COVID-19 vaccine completes China regulator review - media
us.yahoo.com/news/fosun-biontech-covid-19-vaccine-031627609.html


News & Events
February 25, 2021
Small molecule enzyme inhibitor
(sold to Fosun Pharma in 2017, MNKD eligible for royalty payments)

mannkindcorp.com/pipeline-item/small-molecule-enzyme-inhibitor-sold-to-fosun-pharma-mnkd-eligible-for-royalty-payments/

** Not sure if it is related good news for MNKD?

Low single digits? It’s anyone’s guess, but history suggests this won’t amount to much.

how much money will be made? who cares.
BioNTech.....   

Foundation (2008–2013)[edit]
BioNTech was founded in 2008 based on research by Uğur Şahin, Özlem Türeci,[11] and Christoph Huber,[12] with a seed investment of €150 million.[13] The company's activities focus on the development and production of technologies and drugs for individualized cancer immunotherapy.[3] Andreas and Thomas Strüngmann, Michael Motschmann, and Helmut Jeggle were cofounders.[14] In 2009, the acquisition of EUFETS and JPT Peptide Technologies took place.[15][16] Katalin Karikó, whose work on mRNA whilst working at the University of Pennsylvania underpinned the development of Pfizer–BioNTech COVID-19 vaccine,[17] joined BioNTech as a senior vice president in 2013.[18]

I'll tell you what I like these days in this country. Notice the names of the founders are not John or Pat.